Kayne Anderson Rudnick Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-43	Closed	-$5K	–	704
2022 Q1	$5K	Buy	43 +41	+2,050%	+$4K	﹤0.01%	569
2021 Q4	$0	Buy	+2	New	+$218	﹤0.01%	672
2021 Q1	–	Sell	-13	Closed	-$1K	–	750
2020 Q4	$1K	Buy	+13	New	+$966	﹤0.01%	687

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's HZNP Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 43 shares — an estimated $5K sold.

Kayne Anderson Rudnick Investment Management first reported a position in HZNP in Q4 2020 and held it in 3 quarters. The position peaked at $5K in Q1 2022. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Kayne Anderson Rudnick Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Kayne Anderson Rudnick Investment Management sold 43 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $5K.
Kayne Anderson Rudnick Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 3 quarters.
Kayne Anderson Rudnick Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5K in Q1 2022.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.